Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T (2019)
Publication Type: Journal article, Review article
Publication year: 2019
DOI: 10.1080/17474124.2019.1645595
Introduction: The purpose of this review is to highlight the role of biosimilars in early treatment in IBD and introduce ways to facilitate a patient-centric switching process through multidisciplinary approach. Areas covered: We summarize existing scientific literature related to the role of biosimilars in inflammatory bowel disease in terms of early treatment and cost-saving and implementing switching process. Expert opinion: Use of anti-TNF biosimilars in patients has the potential for large drug-acquisition cost-saving, which can be reinvested into early treatment. Managed switched programs for adalimumab can add further benefits in the future.
APA:
Peyrin-Biroulet, L., Danese, S., Cummings, F., Atreya, R., Greveson, K., Pieper, B., & Kang, T. (2019). Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology and Hepatology. https://doi.org/10.1080/17474124.2019.1645595
MLA:
Peyrin-Biroulet, Laurent, et al. "Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach." Expert Review of Gastroenterology and Hepatology (2019).
BibTeX: Download